Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Context Therapeutics (CNTX) from a "hold" to a "sell" rating in the latest report, signaling a negative near‑term view.
• Analyst coverage is mixed — one Strong Buy, seven Buy and one Sell — yielding a MarketBeat average rating of "Moderate Buy" and an average price target of $6.60, with select firms (Piper Sandler, Guggenheim) raising targets into the $5–$7 range.
• Company fundamentals show volatility and pressure: CNTX missed quarterly EPS (‑$0.14 vs. ‑$0.11), analysts forecast ~‑$0.51 EPS for the year, shares trade near $2.59 with a market cap of about $238M, and firms including Lifesci and HC Wainwright have trimmed future EPS estimates citing heavier near‑term losses.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Sunday.

Other analysts have also issued research reports about the stock. Guggenheim reiterated a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th. Lifesci Capital raised shares of Context Therapeutics to a "strong-buy" rating in a research note on Monday, February 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. Piper Sandler boosted their price target on Context Therapeutics from $4.00 to $7.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 24th. Finally, JonesTrading initiated coverage on Context Therapeutics in a research note on Monday, December 22nd. They issued a "buy" rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Context Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $6.60.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $2.59 on Friday. The business's 50 day moving average price is $2.48 and its 200-day moving average price is $1.63. Context Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.62. The firm has a market capitalization of $237.97 million, a price-to-earnings ratio of -6.82 and a beta of 1.96.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). On average, sell-side analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently modified their holdings of the company. Blue Owl Capital Holdings LP increased its position in Context Therapeutics by 0.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company's stock worth $10,926,000 after purchasing an additional 25,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company's stock valued at $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $3,824,000. Marshall Wace LLP increased its holdings in shares of Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company's stock worth $3,812,000 after buying an additional 2,557,448 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company's stock valued at $747,000 after buying an additional 188,202 shares during the period. Hedge funds and other institutional investors own 14.03% of the company's stock.

Key Stories Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target, reflecting stronger upside expectations; this can boost investor sentiment and buying interest. Piper Sandler Raises Context Therapeutics Price Target
• Positive Sentiment: Guggenheim published a Buy rating on CNTX, another institutional endorsement that may support the rally. Guggenheim Buy Rating
• Positive Sentiment: D. Boral Capital issued a Buy rating, adding to the cluster of favorable analyst recommendations. D. Boral Capital Buy Rating
• Positive Sentiment: MSN reports a 13.33% increase in a published price target to $5.78, signaling bullish revision of fair value that can attract momentum traders. Price Target Increased to $5.78
• Negative Sentiment: Lifesci Capital cut multiple 2026 quarterly and full‑year EPS estimates (Q1–Q4 2026 and FY2026 now seen at about ($0.62) vs prior ~$($0.55)); the firm still carries a "Strong‑Buy" rating, but lowered earnings guidance increases short‑term downside risk if fundamentals or cash burn concerns persist.
• Negative Sentiment: HC Wainwright also trimmed Q1–Q4 2026 and multi‑year EPS forecasts (FY2026 lowered to ~$($0.60) from ~$($0.49) and later‑year estimates reduced), signaling analysts expect heavier near‑term losses than previously modeled — a negative for valuation and longer‑term profitability expectations.

About Context Therapeutics

Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.